Collection 01 March 2022

Monthly Readers' Choice

This Collection highlights the newest top-viewed content from Prostate Cancer and Prostatic Diseases. Updated each month, we hope you enjoy reading this selection of articles. PCAN aims to serve as a forum for the sharing and discussion of clinical and translational research developments in all conditions of the prostate, including prostate cancer, prostatitis, and male lower urinary tract symptoms.

Content

The role of COVID-19 in prostate tissue inflammation: first pathological evidence
- Alessio Pecoraro
- Simone Morselli
- Mauro Gacci
Brief Communication14 Apr 2022 Prostate Cancer and Prostatic Diseases
Serum metabolomic analysis of men on a low-carbohydrate diet for biochemically recurrent prostate cancer reveals the potential role of ketogenesis to slow tumor growth: a secondary analysis of the CAPS2 diet trial
- Jen-Tsan Chi
- Pao-Hwa Lin
- Stephen J. Freedland
Article25 Mar 2022 Prostate Cancer and Prostatic Diseases
LHRH sparing therapy in patients with chemotherapy-naïve, mCRPC treated with abiraterone acetate plus prednisone: results of the randomized phase II SPARE trial
- Carsten-Henning Ohlmann
- Michelle Jäschke
- Michael Stöckle
ArticleOpen Access16 Apr 2022 Prostate Cancer and Prostatic Diseases
Real-world evidence of patients with metastatic castration-resistant prostate cancer treated with cabazitaxel: comparison with the randomized clinical study CARD
- Ronald de Wit
- Stephen J. Freedland
- Alicia K. Morgans
ArticleOpen Access17 Jan 2022 Prostate Cancer and Prostatic Diseases
The promising role of new molecular biomarkers in prostate cancer: from coding and non-coding genes to artificial intelligence approaches
- Ana Paula Alarcón-Zendejas
- Anna Scavuzzo
- Luis A. Herrera
Review ArticleOpen Access14 Apr 2022 Prostate Cancer and Prostatic Diseases
The impact of a fasting mimicking diet on the metabolic health of a prospective cohort of patients with prostate cancer: a pilot implementation study
- V. Fay-Watt
- S. O’Connor
- F. J. Sullivan
ArticleOpen Access21 Mar 2022 Prostate Cancer and Prostatic Diseases
Exercise in advanced prostate cancer elevates myokine levels and suppresses in-vitro cell growth
- Jin-Soo Kim
- Dennis R. Taaffe
- Robert U. Newton
ArticleOpen Access12 Feb 2022 Prostate Cancer and Prostatic Diseases
Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score
- Minh-Phuong Huynh-Le
- Roshan Karunamuni
- Tyler M. Seibert
ArticleOpen Access12 Feb 2022 Prostate Cancer and Prostatic Diseases
Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study)
- Daniel J. George
- Neeraj Agarwal
- Neal Shore
ArticleOpen Access21 Feb 2022 Prostate Cancer and Prostatic Diseases
A phase 2 trial of avelumab in men with aggressive-variant or neuroendocrine prostate cancer
- Landon C. Brown
- Susan Halabi
- Andrew J. Armstrong
Article15 Mar 2022 Prostate Cancer and Prostatic Diseases
NEAR trial: A single-arm phase II trial of neoadjuvant apalutamide monotherapy and radical prostatectomy in intermediate- and high-risk prostate cancer
- Lui Shiong Lee
- Adelene Y. L. Sim
- Melvin L. K. Chua
ArticleOpen Access28 Jan 2022 Prostate Cancer and Prostatic Diseases
Low quality of life in men with chronic prostatitis-like symptoms
- Mikio Sugimoto
- Yasukazu Hijikata
- Shunichi Fukuhara
ArticleOpen Access25 Jun 2022 Prostate Cancer and Prostatic Diseases
Long term genitourinary toxicity following curative intent intensity-modulated radiotherapy for prostate cancer: a systematic review and meta-analysis
- Rowan David
- Alex Buckby
- Michael E. O’Callaghan
Review ArticleOpen Access8 Mar 2022 Prostate Cancer and Prostatic Diseases
Social determinants of health: does socioeconomic status affect access to staging imaging for men with prostate cancer
- Brian D. Kelly
- Marlon Perera
- Nathan Papa
Brief CommunicationOpen Access15 Feb 2022 Prostate Cancer and Prostatic Diseases
Cardiovascular risk of gonadotropin-releasing hormone antagonist versus agonist in men with prostate cancer: an observational study in Taiwan
- Yu-Hsuan Joni Shao
- Jian-Hua Hong
- Chao-Yuan Huang
ArticleOpen Access3 Jun 2022 Prostate Cancer and Prostatic Diseases
Awaiting the perfect diagnostic test: optimal prostate cancer care begins without a diagnosis
- Jeffrey J. Tosoian
Editorial2 Feb 2022 Prostate Cancer and Prostatic Diseases
Local versus systemic treatment intensification: what is the optimal strategy for localized prostate cancer?
- Zachary S. Zumsteg
Editorial6 Feb 2022 Prostate Cancer and Prostatic Diseases
Prostate cancer and prostatic diseases is “Your” journal
- Cosimo De Nunzio
Editorial19 Jan 2022 Prostate Cancer and Prostatic Diseases
Goodbye and thanks for the memories
- Stephen J. Freedland
Editorial21 Jan 2022 Prostate Cancer and Prostatic Diseases
Statins and prostate cancer—hype or hope? The epidemiological perspective
- Emma L. Craig
- Konrad H. Stopsack
- Emma H. Allott
Review ArticleOpen Access22 Jun 2022 Prostate Cancer and Prostatic Diseases
Significant changes in macrophage and CD8 T cell densities in primary prostate tumors 2 weeks after SBRT
- Nathanael Kane
- Tahmineh Romero
- Nicholas G. Nickols
Brief CommunicationOpen Access20 Jan 2022 Prostate Cancer and Prostatic Diseases
Prostate cancer detection: a systematic review of urinary biosensors
- Kit Man Chan
- Jonathan M. Gleadle
- Melanie MacGregor
Review Article8 Jan 2022 Prostate Cancer and Prostatic Diseases
The differential diagnostic value of dual-phase ¹⁸F-DCFPyL PET/CT in prostate carcinoma
- Aijuan Tian
- Runlong Lin
- Zhaoyan Zhong
ArticleOpen Access14 Apr 2022 Prostate Cancer and Prostatic Diseases
The EXPANDER-1 trial: introduction of the novel Urocross™ Expander System for treatment of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH)
- Henry H. Woo
- Chi-Ping Huang
- Dean S. Elterman
ArticleOpen Access31 May 2022 Prostate Cancer and Prostatic Diseases

Monthly Readers' Choice

Content

The role of COVID-19 in prostate tissue inflammation: first pathological evidence

Serum metabolomic analysis of men on a low-carbohydrate diet for biochemically recurrent prostate cancer reveals the potential role of ketogenesis to slow tumor growth: a secondary analysis of the CAPS2 diet trial

LHRH sparing therapy in patients with chemotherapy-naïve, mCRPC treated with abiraterone acetate plus prednisone: results of the randomized phase II SPARE trial

Real-world evidence of patients with metastatic castration-resistant prostate cancer treated with cabazitaxel: comparison with the randomized clinical study CARD

The promising role of new molecular biomarkers in prostate cancer: from coding and non-coding genes to artificial intelligence approaches

The impact of a fasting mimicking diet on the metabolic health of a prospective cohort of patients with prostate cancer: a pilot implementation study

Exercise in advanced prostate cancer elevates myokine levels and suppresses in-vitro cell growth

Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score

Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study)

A phase 2 trial of avelumab in men with aggressive-variant or neuroendocrine prostate cancer

NEAR trial: A single-arm phase II trial of neoadjuvant apalutamide monotherapy and radical prostatectomy in intermediate- and high-risk prostate cancer

Low quality of life in men with chronic prostatitis-like symptoms

Long term genitourinary toxicity following curative intent intensity-modulated radiotherapy for prostate cancer: a systematic review and meta-analysis

Social determinants of health: does socioeconomic status affect access to staging imaging for men with prostate cancer

Cardiovascular risk of gonadotropin-releasing hormone antagonist versus agonist in men with prostate cancer: an observational study in Taiwan

Awaiting the perfect diagnostic test: optimal prostate cancer care begins without a diagnosis

Local versus systemic treatment intensification: what is the optimal strategy for localized prostate cancer?

Prostate cancer and prostatic diseases is “Your” journal

Goodbye and thanks for the memories

Statins and prostate cancer—hype or hope? The epidemiological perspective

Significant changes in macrophage and CD8 T cell densities in primary prostate tumors 2 weeks after SBRT

Prostate cancer detection: a systematic review of urinary biosensors

The differential diagnostic value of dual-phase ¹⁸F-DCFPyL PET/CT in prostate carcinoma

The EXPANDER-1 trial: introduction of the novel Urocross™ Expander System for treatment of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH)

Search

Quick links